SUZ12 and neoplasm: The sensitivity has been correlated to certain mutational states, like Suz12 loss in malignant peripheral nerve sheath tumours [31] which leads to an epigenetic switch from histone methylation to histone acetylation, rendering the tumours sensitive to BET inhibitor JQ1.